Re-positioning protein-kinase inhibitors against schistosomiasis

Future Medicinal Chemistry

Volumn 7, Issue 6, 2015, Pages 737-752

  Gelmedin, Verena ^a   Dissous, Colette ^b   Grevelding, Christoph G ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PRAZIQUANTEL; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; ANTISCHISTOSOMAL AGENT;

AFRICA SOUTH OF THE SAHARA; ASCARIASIS; BLOOD VESSEL; CELL MEMBRANE; CHEMICAL MODIFICATION; DRUG REPOSITIONING; DRUG TARGETING; EGG PRODUCTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HELMINTHIASIS; HUMAN; HYGIENE; IN VITRO STUDY; IN VIVO STUDY; INTERMEDIATE HOST; NONHUMAN; ONCHOCERCIASIS; PATHOLOGY; PLATYHELMINTH; PRIORITY JOURNAL; REVIEW; SCHISTOSOMA; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SIGNAL TRANSDUCTION; ZOONOSIS; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PARASITOLOGY; PROCEDURES;

ANIMALS; DRUG REPOSITIONING; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES; SIGNAL TRANSDUCTION;

EID: 84929773417     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.31     Document Type: Review

References (103)

1. WHO. Global Health Estimates www.who.int/healthinfo
2. WHO factsheet Schistosomiasis. www.who.int/mediacentre
3. Grimes JET, Croll D, Harrison WE, Utzinger J, Freeman MC, Templeton MR. The relationship between water, sanitation and schistosomiasis: a systematic review and meta-analysis. PLoS Negl. Trop. Dis. 8(12), e3296 (2014).
4. Cheever AW, Powers KG. Schistosoma mansoni infection in rhesus monkeys: changes in egg production and egg distribution in prolonged infections in intact and splenectomized monkeys. Ann. Trop. Med. Parasitol. 63(1), 83-93 (1969).
5. Cheever AW, Macedonia JG, Mosimann JE, Cheever EA. Kinetics of egg production and egg excretion by Schistosoma mansoni and S. japonicum in mice infected with a single pair of worms. Am. J. Trop. Med. Hyg. 50(3), 281-295 (1994).
6. Bayne CJ. Successful parasitism of vector snail Biomphalaria glabrata by the human blood fluke (trematode) Schistosoma mansoni: a 2009 assessment. Mol. Biochem. Parasitol. 165(1), 8-18 (2009).
7. Knight M, Arican-Goktas HD, Ittiprasert W, Odoemelam EC, Miller AN, Bridger JM. Schistosomes and snails: a molecular encounter. Front. Genet. 5, 230 (2014).
8. Inobaya MT, Olveda RM, Chau TN, Olveda DU, Ross AG. Prevention and control of schistosomiasis: a current perspective. Res. Rep. Trop. Med. 2014(5), 65-75 (2014).
9. Secor WE. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr. Opin. HIV AIDS 7(3), 254-259 (2012).
10. Hatz CFR. Schistosomiasis: an underestimated problem in industrialized countries? J. Travel Med. 12(1), 1-2 (2005).
11. Grobusch MP, Mühlberger N, Jelinek T et al. Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop. J. Travel Med. 10(3), 164-169 (2003).
12. De Laval F, Savini H, Biance-Valero E, Simon F. Human schistosomiasis: an emerging threat for Europe. Lancet 384(9948), 1094-1095 (2014).
13. De Bont J, Vercruysse J. Schistosomiasis in cattle. Adv. Parasitol. 41, 285-364 (1998).
14. Huang Y-X, Manderson L. The social and economic context and determinants of schistosomiasis japonica. Acta Trop. 96(2-3), 223-231 (2005).
15. Gray DJ, Williams GM, Li Y et al. A cluster-randomised intervention trial against Schistosoma japonicum in the Peoples 'Republic of China: bovine and human transmission. PLoS ONE 4(6), e5900 (2009).
16. Wang L-D, Chen H-G, Guo J-G et al. A strategy to control transmission of Schistosoma japonicum in China. N. Engl. J. Med. 360(2), 121-128 (2009).
17. Olveda DU, Li Y, Olveda RM et al. Bilharzia in the Philippines: past, present, and future. Int. J. Infect. Dis. 18, 52-56 (2014).
18. Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 51(1), 83-88 (1994).
19. Botros SS, Bennett JL. Praziquantel resistance. Expert Opin. Drug Discov. 2(S1), S35-S40 (2007).
20. Mwangi IN, Sanchez MC, Mkoji GM et al. Praziquantel sensitivity of Kenyan Schistosoma mansoni isolates and the generation of a laboratory strain with reduced susceptibility to the drug. Int. J. Parasitol. Drugs drug Resist. 4(3), 296-300 (2014).
21. Greenberg RM. Schistosome ABC multidrug transporters: from pharmacology to physiology. Int. J. Parasitol. Drugs Drug Resist. 4(3), 301-309 (2014).
22. Kasinathan RS, Sharma LK, Cunningham C, Webb TR, Greenberg RM. Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel. PLoS Negl. Trop. Dis. 8(10), e3265 (2014).
23. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9(8), 576-596 (1995).
24. Rask-Andersen M, Zhang J, Fabbro D, Schiöth HB. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol. Sci. 35(11), 604-620 (2014).
25. Andrade LF, Nahum LA, Avelar LG et al. Eukaryotic protein kinases (ePKs) of the helminth parasite Schistosoma mansoni. BMC Genom. 12(1), 215 (2011).
26. Knobloch J, Beckmann S, Burmeister C, Quack T, Grevelding CG. Tyrosine kinase and cooperative TGFbeta signaling in the reproductive organs of Schistosoma mansoni. Exp. Parasitol. 117(3), 318-336 (2007).
27. Beckmann S, Quack T, Burmeister C et al. Schistosoma mansoni: signal transduction processes during the development of the reproductive organs. Parasitology 137(3), 497-520 (2010).
28. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 75, 93-109 (2006).
29. Berriman M, Haas BJ, LoVerde PT et al. The genome of the blood fluke Schistosoma mansoni. Nature 460(7253), 352-358 (2009).
30. Protasio AV, Dunne DW, Berriman M. Comparative study of transcriptome profiles of mechanical- and skin-transformed Schistosoma mansoni schistosomula. PLoS Negl. Trop. Dis. 7(3), e2091 (2013).
31. Avelar LG, Nahum LA, Andrade LF, Oliveira G. Functional diversity of the Schistosoma mansoni tyrosine kinases. J. Signal Transduct. 2011, 603290 (2011).
32. Vicogne J, Pin JP, Lardans V, Capron M, Noël C, Dissous C. An unusual receptor tyrosine kinase of Schistosoma mansoni contains a venus flytrap module. Mol. Biochem. Parasitol. 126, 51-62 (2003).
33. Gouignard N, Vanderstraete M, Cailliau K, Lescuyer A, Browaeys E, Dissous C. Schistosoma mansoni: structural and biochemical characterization of two distinct venus kinase receptors. Exp. Parasitol. 132(1), 32-39 (2012).
34. Morel M, Vanderstraete M, Hahnel S, Grevelding CG, Dissous C. Receptor tyrosine kinases and schistosome reproduction: new targets for chemotherapy. Front. Genet. 5, 238 (2014).
35. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1788 (1995).
36. Parrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138, 1427-1433 (1997).
37. Vanderstraete M, Gouignard N, Cailliau K et al. Dual targeting of insulin and venus kinase receptors of Schistosoma mansoni for novel anti-schistosome therapy. PLoS Negl. Trop. Dis. 7(5), e2226 (2013).
38. Blum G, Gazit A, Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39, 15705-15712 (2000).
39. Ahier A, Khayath N, Vicogne J, Dissous C. Insulin receptors and glucose uptake in the human parasite Schistosoma mansoni. Parasite-J. Soc. Fr. Parasitol. 15, 573-579 (2008).
40. You H, Zhang W, Jones MK et al. Cloning and characterisation of Schistosoma japonicum insulin receptors. PLoS ONE 5(3), e9868 (2010).
41. Hahnel S, Quack T, Parker-Manuel SJ et al. Gonad RNA-specific qRT-PCR analyses identify genes with potential functions in schistosome reproduction such as SmFz1 and SmFGFRs. Front. Genet. 5, 170 (2014).
42. Capdevila J, Carrato A, Tabernero J, Grande E. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit. Rev. Oncol. Hematol. 92(2), 83-106 (2014).
43. Buro C, Oliveira KC, Lu Z et al. Transcriptome analyses of inhibitor-treated schistosome females provide evidence for cooperating Src-kinase and TGFβ receptor pathways controlling mitosis and eggshell formation. PLoS Pathog. 9(6), e1003448 (2013).
44. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFβ and BMP pathways. Cell. Signal. 23(11), 1831-1842 (2011).
45. Oliveira KC, Carvalho MLP, Verjovski-Almeida S, LoVerde PT. Effect of human TGF-β on the gene expression profile of Schistosoma mansoni adult worms. Mol. Biochem. Parasitol. 183(2), 132-139 (2012).
46. Glover DM, Hagan IM, Tavares ÁAM. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 12, 3777-3787 (1998).
47. Nigg EA. Polo-like kinases: positive regulators of cell division from start to finish. Curr. Opin. Cell Biol. 10, 776-783 (1998).
48. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660 (2010).
49. Long T, Cailliau K, Beckmann S et al. Schistosoma mansoni Polo-like kinase 1: a mitotic kinase with key functions in parasite reproduction. Int. J. Parasitol. 40(9), 1075-1086 (2010).
50. Swierczewski BE, Davies SJ. A schistosome cAMP-dependent protein kinase catalytic subunit is essential for parasite viability. PLoS Negl. Trop. Dis. 3(8), e505 (2009).
51. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351(Pt 1), 95-105 (2000).
52. Leutner S, Beckmann S, Grevelding CG. Characterization of the cGMP-dependent protein kinase SmcGK1 of Schistosoma mansoni. An. Acad. Bras. Cienc. 83, 637-648 (2011).
53. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat. Rev. Cancer 7(7), 554-562 (2007).
54. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell. Signal. 13(11), 777-785 (2001).
55. Ressurreição M, De Saram P, Kirk RS et al. Protein kinase C and extracellular signal-regulated kinase regulate movement, attachment, pairing and egg release in Schistosoma mansoni. PLoS Negl. Trop. Dis. 8(6), e2924 (2014).
56. Beckmann S, Buro C, Dissous C, Hirzmann J, Grevelding CG. The Syk kinase SmTK4 of Schistosoma mansoni is involved in the regulation of spermatogenesis and oogenesis. PLoS Pathog. 6(2), e1000769 (2010).
57. Seow C-J, Chue S-C, Wong WSF. Piceatannol, a Syk-selective tyrosine kinase inhibitor, attenuated antigen challenge of guinea pig airways in vitro. Eur. J. Pharmacol. 443(1-3), 189-196 (2002).
58. Cambien B, Millet MA, Schmid-Antomarchi H, Brossette N, Rossi B, Schmid-Alliana A. Src-regulated extracellular signal-related kinase and Syk-regulated c-Jun N-terminal kinase pathways act in conjunction to induce IL-1 synthesis in response to microtubule disruption in HL60 cells. J. Immunol. 163(9), 5079-5085 (1999).
59. Zheng J, Ramirez VD. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem. Biophys. Res. Commun. 261(2), 499-503 (1999).
60. Murray CJL, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2197-2223 (2012).
61. Hsieh T-C, Lin C-Y, Lin H-Y, Wu JM. AKT/mTOR as novel targets of polyphenol Piceatannol possibly contributing to inhibition of proliferation of cultured prostate cancer cells. ISRN Urol. 2012, 272697 (2012).
62. Piotrowska H, Kucinska M, Murias M. Biological activity of Piceatannol: leaving the shadow of Resveratrol. Mutat. Res. 750(1), 60-82 (2012).
63. Beckmann S, Leutner S, Gouignard N, Dissous C, Grevelding CG. Protein kinases as potential targets for novel anti-schistosomal strategies. Curr. Pharm. Des. 18(24), 3579-3594 (2012).
64. Yamamoto N, Takeshita K, Shichijo M et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J. Pharmacol. Exp. Ther. 306(3), 1174-1181 (2003).
65. Beckmann S, Hahnel S, Cailliau K et al. Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni. J. Biol. Chem. 286(49), 42325-42336 (2011).
66. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 87(5), 543-552 (2010).
67. Beckmann S, Grevelding CG. Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro. Int. J. Parasitol. 40(5), 521-526 (2010).
68. Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243 (2002).
69. Buro C, Beckmann S, Oliveira KC et al. Imatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effects. PLoS Negl. Trop. Dis. 8(6), e2923 (2014).
70. Beckmann S, Long T, Scheld C, Geyer R, Caffrey CR, Grevelding CG. Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib. Int. J. Parasitol. Drugs Drug Resist. 4(3), 287-295 (2014).
71. Hemer S, Brehm K. In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae. Int. J. Antimicrob. Agents 40(5), 458-462 (2012).
72. Tsai IJ, Zarowiecki M, Holroyd N et al. The genomes of four tapeworm species reveal adaptations to parasitism. Nature 496(7443), 57-63 (2013).
73. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94, 1765-1769 (2006).
74. Katz N, Couto FFB, Araújo N. Imatinib activity on Schistosoma mansoni. Mem. Inst. Oswaldo Cruz 108(7), 850-853 (2013).
75. Da'dara AA, Faghiri Z, Krautz-Peterson G, Bhardwaj R, Skelly PJ. Schistosome Na, K-ATPase as a therapeutic target. Trans. R. Soc. Trop. Med. Hyg. 107(2), 74-82 (2013).
76. Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 137(3), 589-603 (2010).
77. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect. Dis. 10, 153 (2010).
78. Soeiro MNC, Werbovetz K, Boykin DW, Wilson WD, Wang MZ, Hemphill A. Novel amidines and analogues as promising agents against intracellular parasites: a systematic review. Parasitology 1-23 (2013).
79. Hochepied T, Berger FG, Baumann H, Libert C. α1-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 14(1), 25-34 (2003).
80. Kremer JMH, Wilting J, Janssen LHM. Drug-binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40(1), 1-47 (1988).
81. Gambacorti-Passerini C. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571. J. Natl Cancer Inst. 92(20), 1641-1650 (2000).
82. Gambacorti-Passerini CB, Rossi F, Verga M et al. Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells. Mol. Dis. 28(3), 361-372 (2002).
83. Rusche B. The 3Rs and animal welfare - conflict or the way forward? ALTEX 20(Suppl. 1), 63-76 (2003).
84. Azuma M, Nishioka Y, Aono Y et al. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am. J. Respir. Crit. Care Med. 176(12), 1243-1250 (2007).
85. Hegde AH, Punith R, Seetharamappa J. Optical, structural and thermodynamic studies of the association of an anti-leucamic drug imatinib mesylate with transport protein. J. Fluoresc. 22(1), 521-528 (2012).
86. Schistosoma japonicum Genome Sequencing and Functional Analysis Consortium. The Schistosoma japonicum genome reveals features of host - parasite interplay. Nature 460(July), 345-352 (2009).
87. Young ND, Jex AR, Li B et al. Whole-genome sequence of Schistosoma haematobium. Nat. Genet. 44(2), 221-225 (2012).
88. Khayath N, Vicogne J, Ahier A et al. Diversification of the insulin receptor family in the helminth parasite Schistosoma mansoni. FEBS J. 274(3), 659-676 (2007).
89. LoVerde PT, Andrade LF, Oliveira G. Signal transduction regulates schistosome reproductive biology. Curr. Opin. Microbiol. 12(4), 422-428 (2009).
90. Walker AJ, Ressurreição M, Rothermel R. Exploring the function of protein kinases in schistosomes: perspectives from the laboratory and from comparative genomics. Front. Genet. 5, 229 (2014).
91. Vanderstraete M, Gouignard N, Morel M et al. Venus kinase receptors control reproduction in the platyhelminth parasite Schistosoma mansoni. PLoS Pathog. 10(5), e1004138 (2014).
92. Andrade LF De, Mourão MDM, Geraldo JA et al. Regulation of Schistosoma mansoni development and reproduction by the mitogen-activated protein kinase signaling pathway. PLoS Negl. Trop. Dis. 8(6), e2949 (2014).
93. Futreal PA, Coin L, Marshall M et al. A census of human cancer genes. Nat. Rev. Cancer 4(3), 177-183 (2004).
94. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458, 719-724 (2009).
95. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 42(1), 1-40 (2009).
96. Knobloch J, Rossi A, Osman A, LoVerde PT, Klinkert M-Q, Grevelding CG. Cytological and biochemical evidence for a gonad-preferential interplay of SmFKBP12 and SmTbetaR-I in Schistosoma mansoni. Mol. Biochem. Parasitol. 138(2), 227-236 (2004).
97. Carlo JM, Osman A, Niles EG et al. Identification and characterization of an R-Smad ortholog (SmSmad1B) from Schistosoma mansoni. FEBS J. 274(16), 4075-4093 (2007).
98. Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS. Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. Mol. Cell 5(1), 13-25 (2000).
99. Grosse R, Copeland JW, Newsome TP, Way M, Treisman R. A role for VASP in RhoA-Diaphanous signalling to actin dynamics and SRF activity. EMBO J. 22(12), 3050-3061 (2003).
100. Vermeire JJ, Osman A, LoVerde PT, Williams DL. Characterisation of a Rho homologue of Schistosoma mansoni. Int. J. Parasitol. 33(7), 721-731 (2003).
101. Quack T, Knobloch J, Beckmann S, Vicogne J, Dissous C, Grevelding CG. The formin-homology protein SmDia interacts with the Src kinase SmTK and the GTPase SmRho1 in the gonads of Schistosoma mansoni. PLoS ONE 4(9), e6998 (2009).
102. Li Y-H, Xue T-Y, He Y-Z, Du J-W. Novel oncoprotein EPS8: a new target for anticancer therapy. Future Oncol. 9(10), 1587-1594 (2013).
103. Ramachandran H, Skelly PJ, Shoemaker CB. The Schistosoma mansoni epidermal growth factor receptor homologue, SER, has tyrosine kinase activity and is localized in adult muscle. Mol. Biochem. Parasitol. 83(1), 1-10 (1996).